Key Highlights

  • Shares, a penny stock, are trading up about 24.08% today to $1.03.
  • Nine-month 2026 Revenue rose about 26% to $2.6 million, with U.S. sales up 83%.
  • The U.S. footprint nearly doubled to 21 states during the period.
  • Third-quarter adjusted Earnings Per Share missed estimates by about 40%.
  • Management expects healthy double-digit revenue growth in 2027.

IceCure Medical (NASDAQ:ICCM), a Penny Stock trading at $1.03, is rallying today after the company reported nine-month 2026 financial results showing accelerating U.S. growth for its cryoablation technology. IceCure Medical is a commercial-stage Israeli medical device company that develops liquid-nitrogen-based cryoablation systems used as a minimally invasive alternative to surgery for destroying benign and malignant tumors.

U.S. Sales Growth Drives the Nine-Month Results

Nine-month 2026 revenue rose about 26% to $2.6 million from $2.1 million a year earlier, with U.S. sales up 83% over the same period. The company's U.S. footprint nearly doubled to 21 states, while Gross Profit rose about 22% to $762,000.

Losses Widen on Higher Clinical Study Spending

Operating and net loss both rose to about $12.9 million from $10.8 million a year earlier, with Research and Development spending climbing to $6.5 million from $5.1 million on costs tied to the company's ongoing clinical study. Third-quarter adjusted earnings per share missed consensus estimates by roughly 40%. Cash and equivalents stood at about $8.2 million as of September 30, versus $8.9 million at the end of 2025.

Management Points to Continued Growth and International Progress

While the company gave no formal guidance, management said it expects fourth-quarter revenue to exceed the third quarter and projects healthy double-digit revenue growth in 2027. Internationally, the company's technology has received approval in one Asian market, distributor discussions are underway elsewhere, and a regulatory submission in Japan is expected in the first quarter of 2027.

What Comes Next for the Clinical Study and U.S. Expansion

The company's ongoing clinical study now spans four sites, with more expected in the coming months, though management said it is unsure whether its full enrollment target can be reached within three years and plans to discuss timing with regulators. Investors are likely to watch continued U.S. sales team growth and international approval progress as the next catalysts for the stock.